• Qlife Holding will begin a fully partner-funded product-readiness phase with a global pharmaceutical company, targeting a clinical development and commercialization partnership.
• The partner will provide approximately SEK 2.7 million, bringing total collaboration funding to approximately SEK 4.2 million.
• The program comprises 12 weeks of technical work followed by four weeks of mobilization, focusing on sample preparation for Egoo-based treatment monitoring.
• Progression to full-scale product and regulatory development through market clearance depends on successful completion and a subsequent agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qlife Holding AB published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.